Anavex Life Sciences (AVXL) Share-based Compensation (2010 - 2025)
Anavex Life Sciences (AVXL) posted Share-based Compensation of $1.1 million for Q4 2025, down 84.62% sequentially from $7.2 million in Q3 2025, and down 46.13% YoY from $2.1 million in Q4 2024.
Anavex Life Sciences (AVXL) Share-based Compensation (2010 - 2025) Analysis & Trends
Anavex Life Sciences has reported Share-based Compensation for 16 years, with the latest figure at $1.1 million in Q4 2025.
- Quarterly Share-based Compensation fell 46.13% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $13.9 million (up 51.18% YoY) and the FY2025 annual result came in at $11.5 million, up 22.34% from the prior year.
- Share-based Compensation slipped to $1.1 million in Q4 2025 per AVXL's latest filing, from $7.2 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $10.0 million in Q2 2025 and troughed at $1.1 million in Q4 2025.
- A 5-year average of $3.8 million and a median of $3.3 million in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2021 and 2023: Share-based Compensation jumped 377.08% in 2021, then slumped 56.87% in 2023.
- Over 5 years, Share-based Compensation stood at $3.9 million in 2021, then surged by 35.59% to $5.3 million in 2022, then tumbled by 56.87% to $2.3 million in 2023, then dropped by 10.1% to $2.1 million in 2024, then sank by 46.13% to $1.1 million in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $1.1 million, $7.2 million, and $10.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Anavex Life Sciences | 298.40 Mn | 166.65 Mn | - | 1.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.11 Mn |
| Dec 31, 2025 | 1.11 Mn |
| Sep 30, 2025 | 7.20 Mn |
| Sep 30, 2025 | 7.20 Mn |
| Jun 30, 2025 | 10.00 Mn |
| Jun 30, 2025 | 10.00 Mn |
| Mar 31, 2025 | 3.50 Mn |
| Mar 31, 2025 | 3.50 Mn |
| Dec 31, 2024 | 2.06 Mn |
| Dec 31, 2024 | 2.06 Mn |
| Sep 30, 2024 | 1.97 Mn |
| Sep 30, 2024 | 1.97 Mn |
| Jun 30, 2024 | 2.49 Mn |
| Jun 30, 2024 | 2.49 Mn |
| Mar 31, 2024 | 2.65 Mn |
| Mar 31, 2024 | 2.65 Mn |
| Dec 31, 2023 | 2.29 Mn |
| Dec 31, 2023 | 2.29 Mn |
| Sep 30, 2023 | 3.19 Mn |
| Sep 30, 2023 | 3.19 Mn |